Results from a randomized phase III trial examining rituximab in patients with central nervous lymphoma show that treatment with rituximab does not improve response and survival rates – questioning the role of rituximab in this patient population.
Recent Articles
Medicare Poised to Cover CAR T-Cell Therapy
Medicare may soon offer coverage of chimeric antigen receptor (CAR) T-cell therapy for patients with cancer, but with considerable restrictions that aim to rein...
PBM Execs Testify Before Congress About High Drug Prices
It was pharmacy benefit managers’ (PBMs’) turn to testify before Congress during an April 9 Senate Finance Committee hearing as part of an ongoing...
CDC: Opioids Okay for People With Cancer and Sickle Cell Disease
The Centers for Disease Control and Prevention (CDC) has clarified its 2016 guidelines for opioid prescription, stating that the recommendations were not intended to...
California Hospitals and Lawmakers Clash Over Aid-in-Dying Drugs
Approximately two-thirds of California hospitals restrict physicians’ ability to prescribe aid-in-dying medications, despite a law granting patients with terminal illnesses access to drugs that...
International Partnerships Lead to Strides in Pediatric Leukemia in El Salvador
Although acute lymphocytic leukemia (ALL) is relatively rare, it is the most common cancer diagnosed in children, representing approximately one-quarter of cancers diagnosed in...
Current Issue
April 2019, Volume 5, Issue 5
This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.
